NCT05983159 - A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2024

Primary Completion Date

August 31, 2026

Study Completion Date

December 31, 2026

Conditions

Slow-Flow Vascular MalformationFast-Flow Vascular MalformationVascular MalformationsVenous MalformationLymphatic Malformation, Low FlowLymphatic MalformationLymphangiomaArteriovenous MalformationsVenous Malformation, Low FlowCystic HygromaVascular AnomalyVascular AnomaliesPI3K Gene MutationMAP2K1 Gene MutationPIK3CA-related Overgrowth SpectrumArteriovenous Malformation (AVM)KRAS G12CKRAS G12D

Interventions

DRUG

Alpelisib

Oral alpha-specific PI3-kinase inhibitor

DRUG

Mirdametinib

An investigational oral MEK inhibitor

Trial Locations (2)

3052

RECRUITING

Peter MacCallum Cancer Centre, Parkville

RECRUITING

The Royal Children's Hospital, Parkville